TinyGemsBreaks Archive - Page 85 of 122

FridayDec 09, 2022 12:02 pm

TinyGemsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Announces $5M Registered Direct Offering

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced its entry into securities agreements with institutional investors for the purchase and sale of 12,500,000 of the company’s common shares, pursuant to a registered direct offering, and warrants to purchase up to 12,500,000 common shares. According to the update, the combined purchase price for one common share and one warrant will be $0.40. Aggregate proceeds from the offering will be approximately $5.0 million, from which the company expects to use net proceeds for capital expenditures, to increase operating capacity, as well as…

FridayDec 09, 2022 9:59 am

TinyGemsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Announces Former General Motors Federal Government Sales Leader as New GM of Government Sales

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has hired Ronal Dixon as its general manager of government sales; Dixon will focus on U.S. government vehicle procurement programs. With more than four decades of experience, Dixon has an impressive resume, including serving for more than 20 years as a leader on General Motors’ Federal Government Fleet Sales Team, responsible for all aspects of bidding, contract approvals and price negotiations; over the course of his career, Dixon was responsible for selling more than 500,000 units to the U.S. federal government. The strategic hire aligns with Mullen’s 100% EV product…

ThursdayDec 08, 2022 1:46 pm

TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Latest DehydraTECH-CBD Study May Be 1st to Evidence Sustained Drop in Blood Pressure

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global leader in enhancing the speed and efficiency of orally delivered fat-soluble active molecules and drugs, has, since inception, been committed to addressing severe unmet patient needs. Hypertension has been one of its main focus areas. “Lexaria continues to move forward, most recently with the success in its latest human clinical study, HYPER-H21-4. The study may be the first to evidence a sustained drop in blood pressure in normally active patients following multiple weeks of oral cannabidiol (‘CBD’) therapy using the company’s patented DehydraTECH(TM) technology,” reads a recent article. “Since Lexaria began developing DehydraTECH…

ThursdayDec 08, 2022 11:56 am

TinyGemsBreaks – Knightscope, Inc. (NASDAQ: KSCP) CEO Discusses MaaS Business Model, Massive Opportunity on ‘The Shrimp Tank’

Knightscope’s (NASDAQ: KSCP) CEO and Chairman William Santana Li recently appeared on The Shrimp Tank, a podcast series featuring proven entrepreneurs and business leaders discussing how to start, grow and run a successful business. Li joined the program’s hosts, Lee Heisman and Ted Jenkin, to discuss Knightscope’s Machine-as-a -Service (“MaaS”) business model and how the company is using it to improve security while streamlining costs. “Technology can have a massively positive impact on society. Crime has a $2 trillion negative economic impact on the U.S. every single year. What we’ve been doing at Knightscope for almost 10 years is building…

ThursdayDec 08, 2022 11:46 am

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Preliminary Results from Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has released data from its ongoing trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”). The data was presented at the annual meeting for the Society for Neuro-Oncology. Those results indicate that enrolled patients have comparable demographics, including age, gender, race, BSA and KPS; in addition, the percentage of patients continuing on study or having withdrawn is comparable between arms. “Although data are still early, we are pleased with these results in terms of…

ThursdayDec 08, 2022 11:10 am

TinyGemsBreaks – Cepton Inc. (NASDAQ: CPTN) to Showcase Innovative Lidar Solutions at CES 2023

Cepton (NASDAQ: CPTN), a Silicon Valley innovator of high-performance lidar solutions, today announced additional details around its plans for the upcoming CES 2023, slated to be held in Las Vegas, Nevada, from Jan. 5-8, 2023. According to the update, Cepton’s booth (No. 5553, LVCC – West Hall) will feature a Chevy Silverado and a Ford F-150 equipped with the company’s latest vehicle integration solutions. “Developing cutting-edge lidar technology is one thing, but making it usable for consumer vehicles is another,” said Cepton’s CEO and Co-Founder Dr. Jun Pei. “Integrating lidars into everyday passenger cars is more challenging than it seems,…

ThursdayDec 08, 2022 10:53 am

TinyGemsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Announces Auto Veteran as New VP of Commercial Sales

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has announced that Donald Borthwick, previously head of western sales for Ford, will be its new vice president of commercial sales. With more than two decades of commercial vehicle sales experience with Ford, Borthwick has amassed an impressive track record. He grew the company’s west region commercial vehicle sales by 18% during his time there while also achieving regional volume and margin leadership annually. He acquired and developed strategic relationships with key, high-volume accounts from an array of sectors, including consumer retail, food service and package delivery while also securing…

WednesdayDec 07, 2022 2:21 pm

TinyGemsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Deploys K1 Technology for Three New Contracts

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots, has announced three new contracts consisting of 13 new K1 Blue Light Towers and three K1 Retrofit Kits. Two of the new clients are colleges located in Georgia and Texas, marking education as a significant growth sector for the company. The announcement reads, “Knightscope’s K1 Blue Light Emergency Towers and emergency communication Retrofit Kits serve to deter potential negative activities using cellular and satellite communications with solar power to provide additional safety in remote locations. These newer, more advanced wireless systems will save colleges money on both infrastructure and hardware…

WednesdayDec 07, 2022 12:34 pm

TinyGemsBreaks – Vision Energy Corp. (VENG) Announces Symbol Change

Vision Energy (OTCQB: VENG) has announced that, effective at the open of market trading today, its ticker symbol changed from VIHDD to VENG, completing previously reported corporate actions of the company (see news release dated Nov. 7, 2022). According to the update, no action is required by existing shareholders with respect to the ticker symbol change. The company’s common stock will continue trading on the OTCQB, and the CUSIP will remain unchanged. To view the full press release, visit https://ibn.fm/AtHtk About Vision Energy Corp. Vision Energy is a forward-looking energy company developing assets and solutions for the commercial, industrial and…

WednesdayDec 07, 2022 11:04 am

TinyGemsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Presents CYB003 Preclinical Data Amongst Leading Scientists, Academics in Neuropsychopharmacology

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), announced that it presented two posters on its deuterated psilocybin analog, CYB003, at the American College of Neuropsychopharmacology (“ACNP”) annual meeting taking place Dec. 4-7, 2022, in Phoenix, Arizona. According to the update, the data, including new pharmacokinetics (“PK”) findings, further strengthen the therapeutic profile of CYB003 as a novel treatment for major depressive disorder (“MDD”). “These new findings demonstrate the unique PK properties of CYB003 compared with classical psilocybin and further supports our ongoing first-in-human phase 1/2a clinical trial evaluating CYB003 for the treatment…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

TinyGemsBreaks